Crit Care Resusc 11 , 204209 (2009)
The Ghrelin Agonist RM-131 Accelerates Gastric Emptying of Solids and Reduces Symptoms in Patients with Type 1 Diabetes Mellitus
Maryam Daneshpour explains the differences: FDA Safety Update (January 13, 2026) - Finding: No increased risk of #suicidalideation /behavior (SI/B) with GLP-1 RA use
Second, some baseline characteristics, such as included population, duration of study, background therapies and quality of studies are different across included RCTs which are particularly relevant as cardiometabolic effects of GLP-1RAs may differ when these agents are added to insulin, metformin, sulfonylureas, DDP-4 inhibitors and SGLT-2 inhibitors
In addition, they can be expensive and have side effects that reduce the overall quality of life and compliance of patients
We again confirmed that these distinct signaling outcomes were not attributable to the difference in binding site to the BCR, nor to alterations in protein expression of AKT and S6 during stimulation (Appendix Fig